| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8241807 | International Journal of Radiation Oncology*Biology*Physics | 2007 | 6 Pages |
Abstract
Conclusion: Tipifarnib (200 mg/day) concurrent with standard radiotherapy is well tolerated in patients with glioblastoma. Preliminary efficacy results are encouraging.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Elizabeth M.D., Ph.D., Anne M.D., Martine M.D., Muriel Poublanc, Isabelle M.D., Ph.D., Florence M.D., Ph.D., Delphine M.D., Jean M.D., Ph.D., Philippe M.D., Peter M.D., Béatrice M.D., Christine Ph.D.,